Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.40 | N/A | +34.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.40 | N/A | +34.23% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their focus on long-term goals. They did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
While we did not provide guidance, we remain focused on our strategic initiatives.
Supernus Pharmaceuticals reported a strong EPS performance, exceeding expectations by over 34%. However, the lack of revenue data and guidance may leave investors cautious. The stock's slight increase of 0.14% suggests a positive reception to the earnings beat, even without detailed revenue insights.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020